CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 21 enrolled
Drug / intervention
ADHD Medication +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02204410
NCT02204410Phase 4Completed
CompareCT.gov

A Pilot Study of Omega-3 Fatty Acid Supplementation to ADHD Medication in Children With ADHD and Deficits in Emotional Self-Regulation

Massachusetts General Hospital·interventional·Posted Jul 30, 2014·Updated Jun 29, 2017

In Brief

A Phase 4 clinical trial evaluating Omega-3 Fatty Acid and ADHD Medication for Attention Deficit Hyperactivity Disorder and Deficient Emotional Self-Regulation. Completed, enrolled 21 participants across 1 site.

Detailed Summary

This study is a 12-week open-label trial to assess the effectiveness of Omega-3 fatty acids for deficient emotional self-regulation (DESR) as a supplement to Attention Deficit/Hyperactivity Disorder (ADHD) treatment in children and adolescents with Attention Deficit/Hyperactivity Disorder. Subjects will be between the ages of 6-17 and will currently be on medication for their Attention Deficit/Hyperactivity Disorder but still experience DESR traits.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAttention Deficit Hyperactivity Disorder, Deficient Emotional Self-Regulation
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 30, 2014
Enrollment StartJul 1, 2014
Primary CompletionMay 1, 2016
Study CompletionAug 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 11.9 years ago

Interventions

Omega-3 Fatty Aciddietary

ADHD Medicationdrug